To investigate the receptor dependency of HCVpp infection of the permissive cholangiocarcinoma lines, we assessed the ability of anti-CD81 and anti-SR-BI antibodies to inhibit HCVpp (strain H77) infection. Here, CD81 is linked to cholangiocarcinoma.